Science Immunology

Supplementary Materials

The PDF file includes:

  • Fig. S1. HyperTKI could not prevent tumor relapse.
  • Fig. S2. HypoTKI is more potent in suppressing Her2 downstream AKT signaling, inducing apoptosis, and suppressing tumor cell proliferation than HyperTKI in vivo.
  • Fig. S3. HypoTKI is more potent than HyperTKI in controlling tumor growth with fewer side effects.
  • Fig. S4. Characterization of immune cell profile in tumor tissues after EGFR TKI treatment.
  • Fig. S5 HypoTKI could enhance tumor-specific T cell responses.
  • Fig. S6. EGFR TKI induces dsDNA, RNA, and LDH release from tumor cells.
  • Fig. S7 Anti–PD-L1 synergizes with HypoTKI to control advanced large tumor and limit tumor relapse.
  • Fig. S8. HypoTKI combined with anti–PD-L1 causes less toxicity than HyperTKI combined with anti–PD-L1.
  • Fig. S9. Schematic of proposed mechanism for tumor control by EGFR TKI and PD-L1 blockade.
  • Table S1. Key resources.

Download PDF

Other Supplementary Material for this manuscript includes the following:

Files in this Data Supplement: